Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B

Chen,Wei; Liu,Wen‑En; Li,Yan‑Ming; Luo,Shan; Zhong,Yi‑Ming

doi:10.3892/mmr.2015.4369

Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B

Authors:
- Wei Chen
- Wen‑En Liu
- Yan‑Ming Li
- Shan Luo
- Yi‑Ming Zhong
View Affiliations

Affiliations: Department of Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: September 25, 2015 https://doi.org/10.3892/mmr.2015.4369
Pages: 7712-7720

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous nationwide Chinese epidemiological study revealed through isolation of A‑B+ Clostridium difficile strains, which produce toxin B (TcdB), but not toxin A TcdA, that the strains are widespread and more frequent in east Asian countries,. The development of a process capable of detecting TcdB is required in microbiological laboratories in order to facilitate the control of the A‑B+ C. difficile strains, however, no diagnostic reagents have been developed to date. The aim of the present study was to prepare monoclonal antibodies (mAbs) targeting the receptor binding region of TcdB (CDB3), and to establish a double‑antibody sandwich enzyme-linked immunosorbent assay (ds‑ELISA), which can be used for the diagnosis of C. difficile infection. The recombinant protein, glutathione S transferase (GST)‑CDB3 was expressed and purified using an Escherichia coli system. BALB/c mice were immunized with GST‑CDB3 recombinant protein. A hybridoma technique was used for the production of anti‑CDB3 mAb. The hybridoma clones were then screened using indirect ELISA, and anti‑CDB3 mAb was produced in the ascites of the BALB/c mice. Isotyping of anti‑CDB3 mAb was performed using an SBA Clonotyping system/horseradish peroxidase (HRP) ELISA kit. Protein G affinity chromatography was used for purification of anti‑CDB3 mAbs, and the titer and specificity of the anti‑CDB3 mAbs were assessed using indirect ELISA and western blot analysis, respectively. The ds‑ELISA was established using HRP‑labeled anti‑CDB3 mAbd, which were used to detect TcdB clinically in diarrhea stools. A total of five stable hybridoma cell clones (1E7B, 1F8D3, 2F8A6, 3B6F1 and 4A4G2) producing anti‑CDB3 mAb were established. The results of the present study indicated that the immunoglobulin (Ig)G isotype was predominant, as 1E7B2 IgG1 (λ), 2F8A6 IgG2a (κ) and 4A4G2 IgG1 (κ). In addition, the highest titer of anti‑CDB3 mAb (2F8A6 and 4A4G2) was 1:51,200. Western blotting revealed that the 2F8A6 and 4A4G2 mAbs recognized the CDB3 protein specifically. Following anti‑CDB3 mAb (4A4G2) HRP‑labeling, the optimal working concentration was confirmed to be 1:400, and the concentration of coated antibody (2F8A6) was 20 µg/ml. The sensitivity of the ds‑ELISA was 73.33% for the A+B+ toxigenic C. difficile strains, and 86.67% for the A‑B+ toxigenic C. difficile strains, with a specificity of 100% for all. In conclusion, the present study successfully developed novel mAbs specific to CDB3, and developed a ds-ELISA kit with high specificity and sensitivity for the rapid detection of TcdB. This offers a useful tool for the diagnostic assessment of TcdB.

View Figures

View References

1	Hall IC and O'Toole E: Intestinal flora in newborn infants with a description of a new pathogenic anaerobe. Am J Dis Child. 49:390–402. 1935. View Article : Google Scholar
2	George WL, Sutter VL, Goldstein EJ, Ludwig SL and Finegold SM: Aetiology of antimicrobial-agent-associated colitis. Lancet. 1:802–803. 1978. View Article : Google Scholar : PubMed/NCBI
3	Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J and Wilcox MH; Healthcare Epidemiology of America; Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 131:431–455. 2010. View Article : Google Scholar
4	Kelly CP: Current strategies for management of initial Clostridium difficile infection. J Hosp Med. 7(Supple 3): S5–S10. 2012. View Article : Google Scholar : PubMed/NCBI
5	Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, et al: Health care-associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 50:194–201. 2010. View Article : Google Scholar
6	Kelly CP and LaMont JT: Clostridium difficile - more difficult than ever. N Engl J Med. 359:1932–1940. 2008. View Article : Google Scholar : PubMed/NCBI
7	Khanna S and Pardi DS: The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 4:409–416. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT and Kuijper EJ; ECDIS Study Group: Clostridium difficile infection in Europe: A hospital-based survey. Lancet. 377:63–73. 2011. View Article : Google Scholar
9	Gilca R, Hubert B, Fortin E, Gaulin C and Dionne M: Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998–2006. Infect Control Hosp Epidemiol. 31:939–947. 2010. View Article : Google Scholar : PubMed/NCBI
10	Barbut F, Jones G and Eckert C: Epidemiology and control of Clostridium difficile infections in healthcare settings: An update. Curr Opin Infect Dis. 24:370–376. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kuijper EJ, Coignard B and Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control: Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 12(Suppl 6): 2–18. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J and McDonald LC: Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis. 16:197–204. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hall AC, Curns AT, McDonald LC, Parashar UD and Lopman BA: The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1997–2007. Clin Infect Dis. 55:216–223. 2012. View Article : Google Scholar : PubMed/NCBI
14	Khanna S and Pardi DS: Clostridium difficile infection: New insights into management. Mayo Clin Proc. 87:1106–1117. 2012. View Article : Google Scholar : PubMed/NCBI
15	McDonald LC, Lessa F and Sievert D; Centers for Disease Control and Prevention (CDC): Vital signs: Preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 61:157–162. 2012.
16	Miller BA, Chen LF, Sexton DJ and Anderson DJ: Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 32:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A and Minton NP: The role of toxin A and toxin B in Clostridium difficile infection. Nature. 467:711–713. 2010. View Article : Google Scholar : PubMed/NCBI
18	Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CH, Brazier JS, Lumelsky G and Kuijper EJ: Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin Microbiol Infect. 15:1080–1086. 2009. View Article : Google Scholar : PubMed/NCBI
19	Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A and Nord CE: Clostridium difficile infections in a Shanghai hospital: Antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents. 33:339–342. 2009. View Article : Google Scholar
20	Lyerly DM, Krivan HC and Wilkins TD: Clostridium difficile: Its disease and toxins. Clin Microbiol Rev. 1:1–18. 1988.PubMed/NCBI
21	Kim H, Riley TV, Kim M, Kim CK, Yong D, Lee K, Chong Y and Park JW: Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: Impact on laboratory diagnosis. J Clin Microbiol. 46:1116–1117. 2008. View Article : Google Scholar : PubMed/NCBI
22	Iwashima Y, Nakamura A, Kato H, Kato H, Wakimoto Y, Wakiyama N, Kaji C and Ueda R: A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: Genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother. 16:329–333. 2010. View Article : Google Scholar : PubMed/NCBI
23	Elliott B, Squire MM, Thean S, Chang BJ, Brazier JS, Rupnik M and Riley TV: New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J Med Microbiol. 60:1108–1111. 2011. View Article : Google Scholar : PubMed/NCBI
24	Pruitt RN and Lacy DB: Toward a structural understanding of Clostridium difficile toxins A and B. Front. Cell Infect Microbiol. 2:282012.
25	Komatsu M, Kato H, Aihara M, Shimakawa K, Iwasaki M, Nagasaka Y, Fukuda S, Matsuo S, Arakawa Y, Watanabe M, et al: High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis. 22:525–529. 2003. View Article : Google Scholar : PubMed/NCBI
26	Shin BM, Kuak EY, Yoo SJ, Shin WC and Yoo HM: Emerging toxin A–B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis. 60:333–337. 2008. View Article : Google Scholar
27	Hadji-Ghasemi F, Gharagozlou S, Ghods R, Roohi A, Khoshnoodi J and Shokri F: Generation and characterization of a mouse monoclonal antibody with specificity similar to staphylococcal protein A (SPA). Hybrid Hybridomics. 22:33–39. 2003. View Article : Google Scholar : PubMed/NCBI
28	Hajighasemi F, Khoshnoodi J and Shokri F: Development of two murine monoclonal antibodies recognizing human nG1m(a)-like isoallotypic markers. Hybridoma (Larchmt). 27:473–479. 2008. View Article : Google Scholar
29	Hajighasemi F, Gharagozlou S, Ghods R, Khoshnoodi J and Shokri F: Private idiotypes located on light and heavy chains of human myeloma proteins characterized by monoclonal antibodies. Hybridoma (Larchmt). 25:329–335. 2006. View Article : Google Scholar
30	Singh RP, Bandyopadhyay SK, Sreenivasa BP and Dhar P: Production and characterization of monoclonal antibodies to peste des petits ruminants (PPR) virus. Vet Res Commun. 28:623–639. 2004. View Article : Google Scholar : PubMed/NCBI
31	Harlow ED and Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory; New York: pp. 148–242. 1988
32	Hajighasemi F, Saboor-Yaraghi AA and Shokri F: Measurement of affinity constant of anti-human IgG monoclonal antibodies by an Elisa-based method. Iran Immunol. 1:154–161. 2004.
33	Jie Y, Luo HB and Lu DY: Modern microbiological techology and its application. 1st edition. people health press; Beijing: pp. 173–183. 1997
34	Curry S: Clostridium difficile. Clin Lab Med. 30:329–342. 2010. View Article : Google Scholar : PubMed/NCBI
35	Crobach MJ, Dekkers OM, Wilcox MH and Kuijper EJ: European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 15:1053–1066. 2009. View Article : Google Scholar : PubMed/NCBI
36	Wilcox MH: Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect. 18(Suppl 6): 13–20. 2012. View Article : Google Scholar : PubMed/NCBI
37	Boyanton BL, Sural P, Loomis CR, Pesta C, Gonzalez-Krellwitz L, Robinson-Dunn B and Riska P: Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J Clin Microbiol. 50:640–645. 2012. View Article : Google Scholar :
38	Deshpande A, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Pant C and Hernandez AV: Diagnostic accuracy of realtime polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: A metaanalysis. Clin Infect Dis. 53:e81–e90. 2011. View Article : Google Scholar : PubMed/NCBI
39	Longtin Y, Trottier S, Brochu G, Paquet-Bolduc B, Garenc C, Loungnarath V, Beaulieu C, Goulet D and Longtin J: Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 56:67–73. 2013. View Article : Google Scholar
40	Wilkins TD and Lyerly DM: Clostridium difficile testing: After 20 years, still challenging. J Clin Microbiol. 41:531–534. 2003. View Article : Google Scholar : PubMed/NCBI
41	Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A and Krishna S: Diagnosis of Clostridium difficile infection by toxin detection kits: A systematic review. Lancet Infect Dis. 8:777–784. 2008. View Article : Google Scholar : PubMed/NCBI
42	Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S and Gerding DN: Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for Clostridium difficile infections: 2005–2007. Anaerobe. 15:230–233. 2009. View Article : Google Scholar : PubMed/NCBI
43	Albesa-Jové D, Bertrand T, Carpenter EP, Swain GV, Lim J, Zhang J, Haire LF, Vasisht N, Braun V, Lange A, et al: Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS. J Mol Biol. 396:1260–1270. 2010. View Article : Google Scholar : PubMed/NCBI
44	von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J and Sauerborn M: Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet. 233:260–268. 1992. View Article : Google Scholar : PubMed/NCBI